{"id":"switch-ritonavir-boosted-pi","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Lipid abnormalities (elevated cholesterol and triglycerides)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ritonavir-boosted protease inhibitor (PI) regimens combine a primary protease inhibitor with ritonavir, a potent CYP3A4 inhibitor that increases the plasma concentration and half-life of the primary PI. This pharmacokinetic boosting allows for lower doses and less frequent dosing of the primary protease inhibitor while maintaining therapeutic efficacy against HIV protease, which is essential for viral maturation and infectivity.","oneSentence":"A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:23.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT01935674","phase":"PHASE4","title":"Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2013-09","conditions":"HIV, Hypercholesterolaemia","enrollment":43},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT00543101","phase":"PHASE4","title":"Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2007-10","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01231685","phase":"PHASE2","title":"Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2011-12","conditions":"HIV, Hepatitis C, Liver Fibrosis","enrollment":9},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01230580","phase":"PHASE4","title":"Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"2008-11","conditions":"HIV Infection, Acquired Immunodeficiency Syndrome","enrollment":587},{"nctId":"NCT00225017","phase":"PHASE3","title":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-06","conditions":"HIV Infection, Hyperlipidemia","enrollment":50},{"nctId":"NCT00765154","phase":"PHASE4","title":"NNRTI/PI Toxicity Switch to Darunavir Study","status":"TERMINATED","sponsor":"St Stephens Aids Trust","startDate":"2008-10","conditions":"HIV","enrollment":12},{"nctId":"NCT00135356","phase":"PHASE4","title":"Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"HIV-Associated Lipodystrophy Syndrome","enrollment":219},{"nctId":"NCT00528892","phase":"PHASE3","title":"Switching From PI to RALtegravir in HIV Stable Patients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-01","conditions":"HIV Infections","enrollment":282},{"nctId":"NCT00192608","phase":"NA","title":"A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Switch ritonavir-boosted PI","genericName":"Switch ritonavir-boosted PI","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load. Used for HIV-1 infection (as part of antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}